Halozyme Therapeutics (HALO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.28
- Estimate
- $1.82
- Surprise
- +25.5%
- Revenue (period 2026-06-30)
- $481.0M
- Score at report (before → after)
- 6.7 → 6.7/10
Revenue source: xbrl.
How the report landed
Halozyme Therapeutics (HALO) beat the $1.82 estimate with diluted EPS of $2.28 — a large 25.5% upside surprise. TrendMatrix's engine moved from Sell (6.7/10) to Buy (Wait) at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HALO Buy (Wait) at 6.6/10.
3 of the last 4 quarters beat the estimate; this quarter's +25.5% surprise compares with a -18.7% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- Strong earnings beat streak (3/4)
- Positive news sentiment (+0.67)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (0.3% away)
- Leverage penalty (D/E 15.2): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $108.17
- Entry target
- $92.51
- Price target
- $124.40
- Stop
- $84.61
- Upside to target
- +15.0%
The stock trades at 31.2× trailing but 10.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 84 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
HALO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $12.28B
- P/E (fwd)
- 10.4
- P/E (ttm)
- 31.2
- 52-week range
- $61.23–$108.49
- Off 52-week high
- 0.3%
- RSI (14)
- 84
- Volume vs avg
- 0.47×
- Score today
- 6.6/10